EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022

Printer-friendly versionPDF version

This report provides an overview of the risk factors and global trends of dry eye syndrome in the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India)

(PressReleasePoint) -

Dry eye syndrome is one of the most common ophthalmological disorders, causing chronic discomfort in up to 100 million people worldwide, and the disease burden is forecast to increase as the average life expectancy rises, says a new report by research and consulting firm GlobalData.
 
The new report* states that the prevalence of dry eye syndrome, also known as keratoconjunctivitis sicca, primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. However, gender, certain medical conditions, and modern conveniences can all play a part in a sufferer’s condition.
 
As people grow older the production of oil in the body decreases, which reduces tear production and increases evaporation of tears, resulting in dryness of eyes. A greater risk of acquiring dry eye is also experienced by females, with postmenopausal women being particularly at risk, and again, natural biological changes are the reason for this. Sex hormones are known to play a significant role in ocular surface homeostasis, and studies are investigating how disturbances to this homeostasis may result in dry eye syndrome. Anti-androgen therapy, Sjögren’s syndrome, and premature ovarian failure are also associated with androgen deficiency, and may increase the risk for dry eye syndrome, alongside hormone replacement therapy (HRT), which is commonly used among post-menopausal women. Autoimmune diseases and refractive surgeries are also factors which can lead to dry eye syndrome.
 
For Sample Pages, please click or add the below link to the browser:
http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/epicast-report-dry-eye-syndrome-epidemiology-forecast-to-2022/sample&CompanyID=prpoi
 
Contact lens usage and certain medications can induce or exacerbate dry eye symptoms, including some eye medications, and some systemic medications, such as diuretics, antihistamines, anti-cholinergics, anti-depressants, and systemic retinoids, as these drugs reduce the water and mucous production in the eyes. A low intake of omega-3 fatty acids is also a risk factor for dry eye syndrome; researchers hypothesize that omega-3 fatty acids may have a direct effect on the polar portion of the lipid layer of tear film of the eye.
 
In addition, exposure to certain environmental conditions, such as excessive wind, extreme temperatures, low relative humidity, air pollution, and smoking, can increase the risk of developing dry eye syndrome. Modern lifestyle changes, such as exposure to air conditioners and television and computer screens can also reduce the blinking rate of the eyes and cause a condition known as episodic dry eye syndrome.
 
GlobalData expects the number of prevalent cases of dry eye syndrome throughout the US, France, Germany, Italy, Spain, the UK, Japan, China, and India to grow by 2.73% each year, from 195.64 million cases in 2012 to 249.09 million cases by 2022. China will have the largest number of prevalent cases of dry eye syndrome, followed by India.
 
This report provides an overview of the risk factors and global trends of dry eye syndrome in the nine major markets (the US, France, Germany, Italy, Spain, the UK, Japan, China, and India). It includes a 10- year epidemiology forecast of the prevalent cases of dry eye syndrome segmented by sex and age in the 9 major markets.
 
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
 
For further details, please click or add the below link to the browser:
http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/epicast-report-dry-eye-syndrome-epidemiology-forecast-to-2022?utm_source=email&utm_medium=pr&utm_campaign=gdhcprq1&utm_nooveride=1&CompanyID=prpoi
 
Visit report store: http://www.globaldata.com/reportstore
 
For more details contact:
pressreleases@globaldata.com
            
North America:                 +1 646 395 5477
Europe:                                +44 207 753 4299
                                                +44 1204 543 533
Asia Pacific:                         +91 40 6616 6782